Company Filing History:
Years Active: 2025
Title: Innovations of Ming-Shyue Lee in Prostate Cancer Research
Introduction
Ming-Shyue Lee is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of medical research, particularly in the area of prostate cancer. His work focuses on developing biomarkers that can predict the progression of this disease, which is crucial for improving patient outcomes.
Latest Patents
Ming-Shyue Lee holds a patent for "Biomarkers for predicting prostate cancer progression." This invention relates to biomarkers, methods, and assay kits designed to predict prognosis and monitor the progression of prostate cancer. The biomarkers include gene products such as core 1 beta-3-galactosyltransferase (C1GALT1) and ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3GAL1), along with their saccharide substrates/products and galectin-4 gene products. He has 1 patent to his name.
Career Highlights
Ming-Shyue Lee is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work at this institution has allowed him to collaborate with other leading researchers in the field. His innovative approach to cancer research has garnered attention and respect within the scientific community.
Collaborations
Some of his notable coworkers include Pei-wen Hsiao and Chin-Hsien Tsai. Their collaborative efforts have contributed to advancing research in biomarkers and cancer prognosis.
Conclusion
Ming-Shyue Lee's contributions to prostate cancer research through his innovative patents and collaborations highlight the importance of scientific advancements in healthcare. His work continues to pave the way for better diagnostic and prognostic tools in the fight against cancer.